Description: Crystal structure of the insulin receptor kinase in complex with IRS2 KRLB peptide Description: CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR Download all structure-activity data for this target as a CSV file Description: In vitro kinase assay with recombinant kinase domains and peptide substrates. EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen \"Click A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1 M and 10 M against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5 M against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform. Clinically-Relevant Mutations and Pathophysiology \"Click Synonyms: Insulin-resistance syndrome type A [Orphanet: ORPHA2297] Synonyms: Diabetes mellitus, Type II; T2D [OMIM: 125853]Maturity onset diabetesType 2 diabetes mellitus [Disease Ontology: DOID:9352] Synonyms: Hyperinsulinemic hypoglycemia [Disease Ontology: DOID:13317]Hyperinsulinism due to INSR deficiency [Orphanet: ORPHA263458] Synonyms: Pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities [OMIM: 262190] 1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR.(2011)Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. 2. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.(2011)Comprehensive analysis of kinase inhibitor selectivity. 3. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ.(2013)A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. 4. Huang WS, Liu S, Zou D, Thomas M, Wang Y, Zhou T, Romero J, Kohlmann A, Li F, Qi J et al..(2016)Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. 5. Hubbard SR, Wei L, Ellis L, Hendrickson WA.(1994)Crystal structure of the tyrosine kinase domain of the human insulin receptor. 6. Liu TJ, LaFortune T, Honda T, Ohmori O, Hatakeyama S, Meyer T, Jackson D, de Groot J, Yung WK.(2007)Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. 7. Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M et al..(2013)Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. 8. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O\'Connor M, Pirritt C, Sun Y, Yao Y et al..(2009)Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. 9. Ott GR, Tripathy R, Cheng M, McHugh R, Anzalone AV, Underiner TL, Curry MA, Quail MR, Lu L, Wan W et al..(2010)Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. 10. Sabbatini P, Korenchuk S, Rowand JL, Groy A, Liu Q, Leperi D, Atkins C, Dumble M, Yang J, Anderson K et al..(2009)GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. 11. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK.(2005)CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. 12. Wittman M, Carboni J, Attar R, Balasubramanian B, Balimane P, Brassil P, Beaulieu F, Chang C, Clarke W, Dell J et al..(2005)Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. 13. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al..(2010)Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. 14. Wu J, Tseng YD, Xu CF, Neubert TA, White MF, Hubbard SR.(2008)Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2. Type II RTKs: Insulin receptor family: Insulin receptor. Last modified on 08/02/2019. Accessed on 18/05/2020. IUPHAR/BPS Guide to PHARMACOLOGY,